Biopharmaceutics

Staff

Professor　Masahiro Iwaki 　iwakiphar.kindai.ac.jp
	Biopharmaceutical Sciences (3rd grade) Introductory Pharmaceutical Sciences　(1st grade) Scientific Reading in English 2　(3rd grade) Practice of Pharmaceutical Science　(3rd grade) Practice of Clinical Pharmacotherapy　(4th grade)

Lecturer　Tadatoshi Tanino 　taninophar.kindai.ac.jp
	Pharmacokinetics　(3rd grade) Practice of Pharmaceutical Science　(3rd grade) Practice of Clinical Pharmacotherapy　(4th grade)

Assistant Professor　Atsushi Kawase 　kawasephar.kindai.ac.jp
	Biological English　(2ng grade) Practice of Pharmaceutical Science　(3rd grade) Practice of Clinical Pharmacotherapy

Research

1.　Alteration in pharmacokinetics of drugs and factors involved in drug metabolism and disposition on pathological condition
2.　Metabolic activation of drugs and the mechanisms of toxicity expression
3.　Prediction of the pharmacokinetics characteristics and drug interaction from in vitro analysis

Introduction

Biopharmaceutics is the study involving in pharmacokinetics (the kinetics of absorption, distribution, metabolism, and excretion of drugs), pharmacodynamics and drug metabolism using basic, translational and clinical science research methods. Biopharmaceutics also provide effective educational and training experiences for professional (department of pharmacy) and undergraduate (department of pharmaceutical sciences) students and graduate (MS, PhD) students in the areas of bioanalysis, pharmacokinetics/pharmacodynamics, pharmacogenomics, drug transport and metabolism. We investigate the pharmacokinetics in pathological conditions and the physiological factors (CYP450, transporters and nuclear receptors) involved in altered drug metabolism and disposition. We also investigate the drug-natural products interactions which are recently well documented. Finally, we pursue the goal of contribution to the optimal drug therapy in human clinical use. Our research in recent years are 1) prediction of pharmacokinetics based on the in vitro metabolic study, 2) mechanisms of altered pharmacokinetics in chronic inflammatory conditions using model animals, and 3) effect of nuclear receptor on drug disposition in physiological conditions.

Publication (2004-2006)

2006
1. A. Kawase, K. Isaji, A. Yamaoka, N. Kobayashi, M. Nishikawa and Y. Takakura, Enhanced antigen-specific antibody production following polyplex-based DNA vaccination via the intradermal route in mice, Vaccine. 7; 24(27-28), 5535-5545. (2006).
2005
1. Komura H., Kawase A., Iwaki M., Application of substrate depletion assay for early prediction of nonlinear pharmacokinetics in drug discovery: Assessment of nonlinearity of metoprolol, timolol, and propranolol, J. Pharm. Sci., 94, 2656-66 (2005).
2. Komura H. and Iwaki M., Usefulness of hepatocytes for evaluating the genetic polymorphism of CYP2D6 substrates, Xenobiotica., 35, 575-87 (2005).
3. Yamada Y., Boki K., Matsuyama A., Takahashi M., Iwaki M., Adsorption of Cationic Methylene Blue and Anionic Methyl Orange by Crude Drug Starches, J. Appl. Glycosci., 52, 101-106, (2005).
4. Komura H. and Iwaki M., Nonlinear pharmacokinetics of propafenone in rats and humans: application of a substrate depletion assay using hepatocytes for assessment of nonlinearity., Drug. Metab. Dispos., 33, 726-32 (2005).
5. Nishida S., Tsubaki M., Hoshino M., Namimatsu A., Uji H., Yoshioka S., Tanimori Y., Yanae M., Iwaki M., Irimajiri K., Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2., Biochem. Biophys. Res. Commun., 328, 91-7 (2005).
6. Komura H. and Iwaki M., Pharmacokinetics and metabolism of metoprolol and propranolol in the female DA and female Wistar rat: the female DA rat is not always an animal model for poor metabolizers of CYP2D6., J. Pharm. Sci., 94, 397-408 (2005).
7. Nishida S., Matsuoka H., Tsubaki M., Tanimori Y., Yanae M., Fujii Y. and Iwaki M., Mevastatin induces apoptosis in HL60 cells dependently on decrease in phosphorylated ERK., Mol. Cell. Biochem., 269, 109-14 (2005).
2004
1. Kawabata A., Kanke T., Yonezawa D., Ishiki T., Saka M., Kabeya M., Sekiguchi F., Kubo S., Kuroda R., Iwaki M., Katsura K., Plevin R., Potent and metabolically stable agonists for protease-activated receptor-2: evaluation of activity in multiple assay systems in vitro and in vivo., J. Pharmacol. Exp. Ther., 309, 1098-107 (2004).